Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe ...

WOMEN are missing out on diagnosis of a potentially deadly heart condition which affects one in 500 people, says new research ...

Women may be missing a diagnosis of a potentially deadly heart condition due to guidelines that don't account for natural differences in sex and body size, according to a new study led by UCL ...

Trametinib, a mitogen-activated protein kinase (MEK) inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK ...

Hypertrophic cardiomyopathy, or HCM, is a genetic disease in which the heart muscle grows thicker than normal. You might think of the term “big-hearted” to connote something good, says Dr.

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

Discover Trametinib as a promising treatment for severe hypertrophic cardiomyopathy in children with RASopathies.

An initiative to improve care and standardize identification, assessment, referrals, and treatment for patients with HCM has been launched by the AHA.

Study warns of risks of intense training in young athletes: when does exercise benefit or harm children's hearts?

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Cytokinetics (CYTK – Research Report) and keeping the price target at ...

Discover promising gene therapy results from Tenaya Therapeutics, Inc.'s TN-201 and TN-401 projects, potential impact on ...